Overview

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy.
Phase:
Phase 2
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Eslicarbazepine acetate